Diabetes Clinical Trials in Washington

Showing 261-280 of 382 trials

A Performance Evaluation of the Enlite 3 Sensor

NCT02649010

The purpose of this study is to support the use of the Enlite 3 sensor in arm and thigh in subjects age 14 - 75 years and provide additional characterization of the Enlite 3 sensor performance in arm in subjects age 14 - 75 years.

Type 1 Diabetes

Medtronic MiniMed, Inc.Started Jan 2016

Walnut Creek, California, United States • Renton, Washington, United States

COMPLETEDPhase 336 miles

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

NCT00859898

The primary purpose of this study is to compare the change from baseline in hemoglobin A1C achieved with dapagliflozin 10 mg in combination with metformin XR as compared with metformin XR monotherapy and compared with Dapagliflozin monotherapy, after 24 weeks of oral administration of double-blind treatment. The safety of treatment with dapagliflozin will also be assessed in this study

Type 2 Diabetes Mellitus

AstraZeneca1,093 participantsStarted Apr 2009

Ozark, Alabama, United States • Tempe, Arizona, United States • Tempe, Arizona, United States +120 more locations

A Performance Evaluation of the Enlite 3 Sensor

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

Diabetes Trials in Other Cities

Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin

Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus

Glucose Meter Study

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus

A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.

Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

Other Conditions in Washington